anti-MSR1 antibody

Anti-MSR1 antibody is a research-stage monoclonal antibody that targets macrophage scavenger receptor 1 (MSR1, also known as CD204 or SR-A). Developed primarily by Regeneron, these antibodies (including clones such as H1H21234N, REGN4320, and REGN4322) bind to MSR1, a trimeric membrane glycoprotein receptor expressed on macrophages and dendritic cells. MSR1 is involved in the endocytosis of modified low-density lipoproteins (LDL) and plays a key role in lipid metabolism, inflammatory signaling, and tissue remodeling. In preclinical studies, anti-MSR1 antibodies have been investigated for the treatment of atherosclerosis, inflammatory conditions such as arthritis and colitis, and dystrophic cardiac fibrosis associated with Duchenne muscular dystrophy (DMD). Additionally, these antibodies have been utilized as the targeting component of antibody-drug conjugates (ADCs) to deliver therapeutic payloads, such as liver X receptor (LXR) agonists, directly to MSR1-expressing macrophages.